

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

BEMPEDOIC ACID WITH EZETIMIBE FOR TREATING PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA, NICE TA694, APRIL 2021

RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
BEMPEDOIC ACID tablets (NILEMDO®▼) BEMPEDOIC ACID AND EZETIMIBE tablets (NUSTENDI®▼)	Bempedoic acid: adenosine triphosphate-citrate lyase (ACL) inhibitor Ezetimibe: inhibits the absorption of cholesterol	Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet	Final	NICE TA694 – recommended

MSEMOC recommendation:

Bempedoic acid with ezetimibe is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, in accordance with NICE technology appraisal recommendations.

[NICE TA694](#) recommendation:

1.1 Bempedoic acid with ezetimibe is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if:

- statins are contraindicated or not tolerated,
- ezetimibe alone does not control low-density lipoprotein cholesterol well enough, and
- the company provides bempedoic acid and bempedoic acid with ezetimibe according to the commercial arrangement.

Bempedoic acid with ezetimibe can be used as separate tablets or a fixed-dose combination.

1.2 This recommendation is not intended to affect treatment with bempedoic acid with ezetimibe that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

For further information refer to the [Summary of Product Characteristics for bempedoic acid with ezetimibe](#) or [Summary of Product Characteristics for bempedoic acid](#).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia: https://www.nice.org.uk/guidance/ta694
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC
Date Approved	July 2021
Review Date	July 2026 or sooner if subject to any new updates nationally